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The estimated exposure thresholds for RBC acetylcholinesterase (AChE) inhibition and plasma butyrylcholinesterase (BuChE) inhibition were listed incorrectly in the Results as "99% available RBC AChE, and 90% available plasma BuChE." The correct values are 99.98% for available RBC AChE and 96.25% for available plasma BuChE.

In addition, the RBC AChE level associated with a 15% cognitive deficit, based on data from Farahat et al. ([@c1]), was derived incorrectly as $BM_{\text{RBC}–\text{AChE}} = \left( {100 - 80} \right)/100 = 0.20$. The correct value is $BM_{\text{RBC}–\text{AChE}} = \left( {100 - 80} \right)/80 = 0.25$. The estimate shown in the original [Figure 5](#f5){ref-type="fig"} for the level of $BM_{\text{AChE}}$ associated with a 15% cognitive deficit in Farahat et al. ([@c1]) also was incorrect. The corrected figure is included in this erratum.

![Predictions of human-specific cognitive deficits from measurable biomarkers of exposure. $BM_{\text{CPF}},BM_{\text{AChE}}$, and $\text{BM}_{\text{BuChE}}$, are the independent biomarker of exposure variables for Equation 2 and correspond to peak plasma chlorpyrifos (CPF) concentration, minimum blood acetylcholinesterase (AChE) inhibition and minimum blood butyrylcholinesterase (BuChE) inhibition, respectively. Dashed lines represent 95% prediction intervals, and the solid circle (•) represents measured fractional cognitive deficit data from Farahat et al. ([@c1]) using the differences in performance of the Benton Visual Retention Test between the exposed and unexposed groups and fractional plasma AChE activity from the reported plasma AChE activity.](ehp-126-099001-g0005){#f5}

The authors confirm that these changes do not affect the study conclusions.

The authors regret these errors.
